NCT01266876

Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia

A Randomized, Double-Blind, Placebo-Controlled, 12-Week Study of the Safety and Efficacy of REGN727 in Patients With Heterozygous Familial Hypercholesterolemia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy and safety of REGN727/SAR236553 in participants diagnosed with heterozygous familial hypercholesterolemia (heFH)

Conditions

• Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	Alirocumab	Alirocumab two SC injections in the abdomen only.
DRUG	Placebo	Placebo two SC injections in the abdomen only.

Timeline

• Start date: 2011-01-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2010-12-24
• Last updated: 2015-09-22
• Results posted: 2015-09-22

Locations

22 sites across 2 countries: United States, Canada